A POD derived from the LLNA EC3 of 3.6% was determined leading to a favourable NGRA conclusion and a maximum use concentration of 0.36%. DNA Repair inhibitor This was supported by a traditional risk assessment based on the available animal data for resorcinol.A prenatal developmental toxicological study was conducted to evaluate the safety of an…[Read more]